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Abstract SIOPEN 2015 : High frequency of subclonal ALK mutations in high risk 
neuroblastoma patients. A SIOPEN study. 
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Introduction:  
In neuroblastoma (NB), activating ALK receptor tyrosine kinase point mutations are 
detected in 8–10% at diagnosis using conventional sequencing. To determine the 
potential occurrence and the prognostic impact of ALK mutations in a series of high 
risk NB patients we studied ALK variation frequencies using targeted deep 
sequencing in samples of patients enrolled in the SIOPEN HR-NBL01 study. 
 
Methods:  
To date, a series of 326 diagnostic high risk NB samples enrolled in the HRNBL trial 
has been analyzed, focusing on the exons 23, 24 and 25 containing the F1174, 
F1245 and R1275 hotspots respectively. DNA was amplified via a two-step PCR 
approach, the second step consisting of addition of sample-specific barcodes for 
targeted resequencing in a single experiment. Amplicon sequencing (Illumina 
HiSeq2500) achieved an extremely high depth over the relevant hotspot (80,000X). 
The background base variability (error rate) in 32 control samples was 0.017%+/-
0.010 at the studied position. Given the mean coverage and error rate, a base 
frequency >0.06% is significantly different from background noise (Fisher’s exact 
test). 
 
Results:  
At the F1174 hotspot, mutations were observed in 21/326 samples. For 11 cases, 
these mutations, observed with mutated allele fractions of >20%, occurred at a clonal 
level, and in 10 additional cases they occurred at a sub-clonal level (range of 
mutated allele fractions: 0.207% - 4.195%). At the R1275 hotspot, mutations were 
observed in 26/326 samples, 12 at a clonal and 14 at a sub-clonal level. All clonal 
mutations were validated by Sanger sequencing. In one case, 2 sub-clonal ALK 
mutations (2.997% and 8.943%) were observed at the same position at the hotspot 
R1275 with another mutation observed at the hotspot F1174. Validation of all 
mutations observed at a sub-clonal level and analysis of other samples from 
collaborating groups is currently ongoing. Correlation between these findings and 
clinical and biological parameters will be established.  
 
 
Discussion:  
Our ongoing study documents a high frequency of clonal (7%) and sub-clonal ALK 
mutations (7.9%) in high risk NB patients. These findings are of utmost clinical 
importance given the potential role of ALK mutations in clonal evolution and relapse.   
 
 
 
